Vanguard disaggregates holdings after realignment; CSR shows 0% stake (CSR)
Rhea-AI Filing Summary
Centerspace reports a Schedule 13G/A filing showing The Vanguard Group holds 0% of Centerspace common stock as of 03/13/2026. The filing states Vanguard's subsidiaries were disaggregated after an internal realignment on 01/12/2026, and the report reflects 0% beneficial ownership and zero voting and dispositive power.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026. It lists Vanguard's address in Malvern, PA, and affirms no other single person holds more than 5% of the class.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership following internal reorganization.
The filing lists The Vanguard Group with 0% beneficial ownership and zero voting and dispositive power as of 03/13/2026. It cites an internal realignment on 01/12/2026 and reliance on SEC Release No. 34-39538 for disaggregation.
Implications include a clear public record that Vanguard, in this filing, does not hold reportable shares; subsequent filings would show any change in holdings.
Filing documents procedural disaggregation and confirms sub‑entities report separately.
The submission explains that certain subsidiaries will report separately post‑realignment and that The Vanguard Group "no longer has, or is deemed to have, beneficial ownership" of those securities per the cited release. The report includes standard ownership items: amount beneficially owned 0, percent 0%, and zero voting/dispositive powers.
Regulatory watchers should note the cited SEC release and the signature block dated 03/26/2026 for record completeness; cash‑flow treatment and holdings by specific sub‑entities are not enumerated here.
FAQ
What does Vanguard report in the Centerspace (CSR) Schedule 13G/A?
Does the filing show Vanguard retains voting or dispositive power in CSR?
Who signed the Schedule 13G/A for CSR and when?
Does the filing identify any holder with more than 5% of CSR?
Why does the filing reference SEC Release No. 34-39538?